Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
AssigneeAcademia Sinica
InventorsChi-Huey Wong, Chung-Yi Wu, Che Ma, Han-Chung Wu
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions and methods of use comprising antibodies or binding fragments thereof further comprising universal Fc glycoforms.
Claims19
An isolated monoclonal antibody or antigen-binding fragment thereof that binds to Neu5Acα2→3Galβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1, wherein the antibody or antigen-binding fragment thereof comprises a glycan attached to Asn-297 of the Fc region, wherein the glycan has the formula:
- Sia2( α2-6)Gal2GlcNAc2Man3GlcNAc2, as in the structure shown in FIG. 1, and wherein the antibody or antigen-binding fragment thereof comprises an H-CDR1, an H-CDR2, an H-CDR3, an L-CDR1, an L-CDR2, and an L-CDR3, wherein:
- (i) the H-CDR1 comprises the sequence of SEQ ID NO:152 (GFSLTSYG);
- (ii) the H-CDR2 comprises the sequence of SEQ ID NO:153 (IWGEGST);
- (iii) the H-CDR3 comprises the sequence of SEQ ID NO:154 (AMTGTAY);
- (iv) the L-CDR1 comprises the sequence of SEQ ID NO:149 (SSVSY);
- (v) the L-CDR2 comprises the sequence of SEQ ID NO:150 (DTS);
- and
- (vi) the L-CDR3 comprises the sequence of SEQ ID NO:151(HQWSSSPHT).
An isolated monoclonal antibody or antigen-binding fragment thereof that binds to Neu5Acα2→3Galβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1, wherein the antibody or antigen-binding fragment thereof comprises a glycan attached to Asn-297 of the Fc region, wherein the glycan has the formula:
- Sia2(α2-6)Gal2GlcNAc2Man3GlcNAc2, as in the structure shown in FIG. 1, and wherein the antibody or antigen-binding fragment thereof comprises an H-CDR1, an H-CDR2, an H-CDR3, an L-CDR1, an L-CDR2, and an L-CDR3, wherein:
- (i) the H-CDR1 comprises the sequence of SEQ ID NO:207;
- (ii) the H-CDR2 comprises the sequence of SEQ ID NO:208;
- (iii) the H-CDR3 comprises the sequence of SEQ ID NO:209;
- (iv) the L-CDR1 comprises the sequence of SEQ ID NO:204;
- (v) the L-CDR2 comprises the sequence of SEQ ID NO:205;
- and
- (vi) the L-CDR3 comprises the sequence of SEQ ID NO:206.
An isolated monoclonal antibody or antigen-binding fragment thereof that binds to Neu5Acα2→3Galβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1, wherein the antibody or antigen-binding fragment thereof comprises a glycan attached to Asn-297 of the Fc region, wherein the glycan has the formula:
- Sia2(α2-6)Gal2GlcNAc2Man3GlcNAc2, as in the structure shown in FIG. 1, and wherein the antibody or antigen-binding fragment thereof comprises an H-CDR1, an H-CDR2, an H-CDR3, an L-CDR1, an L-CDR2, and an L-CDR3, wherein:
- (i) the H-CDR1 comprises the sequence of SEQ ID NO:217;
- (ii) the H-CDR2 comprises the sequence of SEQ ID NO:218;
- (iii) the H-CDR3 comprises the sequence of SEQ ID NO:219;
- (iv) the L-CDR1 comprises the sequence of SEQ ID NO:214;
- (v) the L-CDR2 comprises the sequence of SEQ ID NO:215;
- and
- (vi) the L-CDR3 comprises the sequence of SEQ ID NO:216.
An isolated monoclonal antibody or antigen-binding fragment thereof that binds to Neu5Acα2→3Galβ1→3GalNAcβ1→3Galαl→4Galβ1→4Glcβ1, wherein the antibody or the antigen-binding fragment thereof comprises a glycan attached to Asn-297 of the Fc region, wherein the glycan has the formula:
- Sia2(α2-6)Gal2GlcNAc2Man3GlcNAc2, as in the structure shown in FIG. 1, and wherein the antibody or antigen-binding fragment thereof comprises an H-CDR1, an H-CDR2, an H-CDR3, an L-CDR1, an L-CDR2, and an L-CDR3, wherein:
- (i) the H-CDR1 comprises the sequence of SEQ ID NO:227;
- (ii) the H-CDR2 comprises the sequence of SEQ ID NO:228;
- (iii) the H-CDR3 comprises the sequence of SEQ ID NO:229;
- (iv) the L-CDR1 comprises the sequence of SEQ ID NO:224;
- (v) the L-CDR2 comprises the sequence of SEQ ID NO:225;
- and
- (vi) the L-CDR3 comprises the sequence of SEQ ID NO:226.
Dependencies are inferred from the claim text.